Absolute Contraindications for Transdermal Estrogen Patch and Progesterone
Transdermal estrogen patch and progesterone therapy should be avoided in women with unexplained vaginal bleeding, history of stroke/TIA/MI/PE/VTE, breast or endometrial cancer, and active liver disease 1.
Absolute Contraindications (Avoid Use)
The 2015 Endocrine Society Clinical Practice Guideline provides the clearest framework for when menopausal hormone therapy (MHT) should not be used 1:
- Unexplained vaginal bleeding - Must be evaluated before initiating therapy
- Cardiovascular events - Prior stroke, transient ischemic attack (TIA), myocardial infarction (MI), pulmonary embolism (PE), or venous thromboembolism (VTE)
- Active or prior breast cancer
- Active or prior endometrial cancer
- Active liver disease
Conditions Requiring Extreme Caution
The guideline also identifies conditions where clinicians should exercise significant caution, though these are not absolute contraindications 1:
- Diabetes mellitus
- Hypertriglyceridemia
- Active gallbladder disease
- Increased risk of breast cancer (family history, genetic mutations, dense breast tissue)
- Increased cardiovascular disease risk
- Migraine with aura
Important Nuances About Transdermal Formulations
While the contraindications above apply to all forms of MHT, transdermal estrogen has a superior safety profile compared to oral estrogen for certain high-risk populations. Recent research demonstrates that transdermal estrogen does not increase VTE risk in healthy postmenopausal women 2, and may be safer in women with:
- Prior VTE (two studies showed decreased coagulability and no increased recurrent VTE risk) 2
- Elevated body mass index 2
- Prothrombotic genetic polymorphisms 2
- Proinflammatory comorbidities 2
However, this does NOT mean transdermal estrogen is safe in women with active VTE or recent cardiovascular events - these remain absolute contraindications regardless of route 1.
Critical Clinical Pitfalls
Age and timing matter: Even without absolute contraindications, MHT should generally not be initiated in women >60 years old or >10 years past menopause due to increased cardiovascular risk 1. This is a critical safety consideration that supersedes route of administration.
Progestogen is mandatory: Women with an intact uterus require continuous combined estrogen plus progestogen to prevent endometrial hyperplasia and cancer 1. Cyclical regimens provide insufficient long-term endometrial protection 3.
Dose considerations: There appears to be a dose-response relationship with stroke risk. Transdermal estrogen doses >50 mcg may increase stroke risk 4, so use the lowest effective dose.